Cardiac amyloidosis medical therapy

Jump to navigation Jump to search

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis medical therapy

CDC onCardiac amyloidosis medical therapy

Cardiac amyloidosis medical therapy in the news

Blogs on Cardiac amyloidosis medical therapy

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]; Cafer Zorkun, M.D., Ph.D. [4]; Lakshmi Gopalakrishnan, M.B.B.S. [5]

Overview

Medical Therapy

Acute Pharmacotherapy

Pacemaker

A pacemaker may be needed if the conduction system is involved.

Supportive Measures

Physical activity may continue as long as the patient can tolerate it.

Diet restrictions vary with the extent of cardiomyopathy and heart failure. These may include salt and/or fluid restrictions.

References

  1. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA (1985). "Selective binding of nifedipine to amyloid fibrils". The American Journal of Cardiology. 55 (13 Pt 1): 1646. PMID 4003315. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  2. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA (1985). "Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents". The American Journal of Cardiology. 55 (13 Pt 1): 1645. PMID 4003314. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  3. Rubinow A, Skinner M, Cohen AS (1981). "Digoxin sensitivity in amyloid cardiomyopathy". Circulation. 63 (6): 1285–8. PMID 7014028. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  4. Mathew V, Olson LJ, Gertz MA, Hayes DL (1997). "Symptomatic conduction system disease in cardiac amyloidosis". The American Journal of Cardiology. 80 (11): 1491–2. PMID 9399732. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  5. Mathew V, Chaliki H, Nishimura RA (1997). "Atrioventricular sequential pacing in cardiac amyloidosis: an acute Doppler echocardiographic and catheterization hemodynamic study". Clinical Cardiology. 20 (8): 723–5. PMID 9259166. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)


Template:WikiDoc Sources